EBV CTL epitopes

US6699477B2 · kind B2 · utility

Assignees

• The Council of the Queensland Institute of Medical Research · AU
• CSL LIMITED · AU
• BIOTECH AUSTRALIA PTY. LTD. · AU
• THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH · AU
• The University of Melbourne · AU
• COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION · AU

Inventors

• Rajiv Khanna · Bowen Bridge, AU
• Beverley Mavis Kerr · Cleveland, AU
• Ihor Stephan Misko · Brisbane, AU
• Denis James Moss · Brisbane, AU
• Scott Burrows · Bald Hills, AU

Key dates

• Filing date: Aug 1, 2001
• Grant date: Mar 2, 2004
• Expiry date: Aug 1, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides an isolated cytotoxic Epstein-Barr virus T-cell epitope having the amino acid sequence TYSAGIVQI (SEQ ID NO: 34) which can be formulated as a water-in-oil formulation, and vaccine compositions comprising said epitope, optionally with additional epitopes.